Yeast supersuppressor genes capable of masking the effects of several lysine mutant genes (lyl1l, lyg..ily,I1) were studied with respect to their effects on the respective enzymes (saccharopine dehydrogenase, saccharopine reductase, and a-aminoadipic acid reductase). In all strains tested, the supersuppressors functioned by allowing enzyme synthesis not found in the unsuppressed mutant. Studies by optical methods of saccharopine dehydrogenase and saccharopine reductase extracted from suppressed ly1 l and lyg-l cells, respectively, revealed that the Km values for these enzymes were significantly greater than those found in wild type. Saccharopine dehydrogenase from suppressed IY9-l cells was found to have K,, values similar to wild type. These findings are consistent with the inference that a supersuppressor may act by enabling nonsense codons to be read, producing altered enzyme protein. Recent findings that lysine degradation in mammals may involve saccharopine and that the human diseases, hyperlysinemia and saccharopinuria, may be due to metabolic blocks in this route of lysine degradation suggest the ly1 l and lyg9l yeast mutants as models for the human condition and its possible euphenic treatment.
Since the discovery of supersuppressors in yeast (9) , the evidence supporting their similarity to the bacterial nonsense suppressors has been largely inferential and indirect (16) . Recent direct findings (6) , however, have demonstrated the comparability of the two systems.
Several theories proposed for the mechanism of nonsense suppression have been reviewed by Gorini and Beckwith (7) . The principal theoretical model assumes a nonsense codon in the supersuppressible allele, leading to chain termination and an incomplete mutant protein.
The supersuppressor gene is assumed to have mutated to form an altered species of transfer ribonucleic acid (tRNA) capable of reading the nonsense codon and of inserting an amino acid at the nonsense site, enabling chain completion (1) .
The observation that supersuppressor genes in yeast are dominant, allele specific, and locus nonspecific (9) is consistent with this model.
The current study describes the isolation and characterization of two supersuppressors in yeast. These were recognized in terms of their effects on 1 A summary of this paper was presented at the 68th Annual Meeting of the American Society for Microbiology, 5- several nonallelic mutant lesions (lyl-l, lys9l Y2-l), controlling three different enzymes after a-aminoadipic acid (3) (a-AAA) in the lysine biosynthetic pathway (Fig. 1) . This, at first, made us suspect the existence of an alternate pathway between a-AAA and lysine, but a more comprehensive genetic study (A. Roshanmanesh, Ph.D. Thesis, Southern Illinois University, Carbondale, 1968) demonstrated that the suppression was caused by supersuppressors rather than pathway suppressors. The effects of these supersuppressors at the level of enzyme was the subject of the present study. The properties of ca-AAA reductase (ly2 l), saccharopine reductase (1y9 l), and saccharopine dehydrogenase (lyi-1) have been compared in wild-type, mutant, and supersuppressed mutant strains. VOL. 101, 1970 SUPERSUPPRESSOR GENES After centrifugation, the pellets were redissolved in 0.1 M potassium phosphate buffer (pH 6.8) and either used directly (partially purified enzyme) or after dialysis for 24 hr in the indicated buffers (dialyzed, partially purified enzyme).
Incubation of enzyme preparations with radioactive substrates. Enzymatic conversion of either labeled a-AAA or labeled lysine to saccharopine was studied by adapting a system previously described (18) .
A 30-pliter sample of enzyme was incubated with 0.5 MAc of either L-lysine-6-14C (specific activity, 2.58 mc/mmole) or DL-a-AAA-6-14C (specific activity, 3 .48 mc/mmole) and 10 Mliters of a solution of the appropriate cofactors. Control incubations with no cofactor substituted 10, liters of buffer for the cofactor solutions.
For the lysine to saccharopine conversion, the stock cofactor solution contained 10 mg of reduced nicotinamide adenine dinucleotide (NADH) and 10 mg of a-ketoglutaric acid (a-KG) per ml, and, for the conversion of a-AAA to saccharopine, the stock cofactor solution contained 10 mg of ATP per ml. After incubation of 2 to 4 hr, the reactions were sampled and spotted directly in 5-,liter portions on 589 Orange Ribbon paper strips (Schleicher & Schuell Co., Keene, N.H.) for descending chromatography. After chromatography, the strips were dried and the locations and intensities of radioactive areas were determined by scanning with a Radiochromatogram Strip Scanner (Actigraph III; Nuclear-Chicago Corp., Cleveland, Ohio). The chromatographic migrational direction is from left to right on all figures with the base line and solvent front indicated, respectively, by B.L. and S.F.
Counting parameters were as follows unless otherwise indicated: high voltage, 950 v; scan speed, 60 cm/ hr; background suppression, none; full scale, 3,000 counts/min; time constant, 10 sec; collimator slit width, 1.5 mm. Known standards of lysine, saccharopine, and a-AAA were included as references in each solvent system.
Incubation of whole cells with radioactive substrates. Various strains of Saccharomyces were grown in COMP medium, harvested, and washed 3 times in 0.07 M monobasic potassium phosphate and finally in 0.07 M monobasic potassium phosphate containing 3% glucose.
Approximately 625 mg of packed cells was incubated for 6 hr at 30 C with 2.0,uc (specific activity, 3.48 SUPERSUPPRESSOR GENES AND LYSINE BIOSYNTHESIS mc/mmole) of a-AAA-6-14C and 0.5 ml of 0.07 M potassium phosphate containing 3% glucose.
Cells and media were then separated by centrifugation. The cells were washed once in distilled water and resuspended to the original volume in distilled water for hot-water extraction of the amino acid pool. Control experiments demonstrated that pool extraction at autoclave temperatures (121 C) destroyed a significant part of the a-AAA, whereas 20 min in a boiling water bath extracted the a-AAA quantitatively without significant destruction. The centrifuged hot-water extract was spotted in 20-,uliter portions on paper strips for descending paper chromatography.
Spectrophotometric assay of saccharopine dehydrogenase and saccharopine reductase. Saccharopine dehydrogenase and saccharopine reductase activities were estimated by slight modification of the optical assays of Saunders and Broquist (22) and Jones and Broquist (14) . Our incubation mixtures for saccharopine dehydrogenase assay contained: NADH, 2
Jumoles; a-KG, 50,umoles; L-lysine, 50 jAmoles, in a total volume of 3 ml. These concentrations gave somewhat enhanced sensitivity and were capable of detecting 1% of the wild-type enzyme level. For saccharopine dehydrogenase, the assay involved following the oxidation of NADH at 339 nm in the presence of substrates (a-KG and L-lysine) and enzyme ( Fig. 1) . Saccharopine reductase activity was assayed by following the reduction of nicotinamide adenine dinucleotide phosphate (NADP) at 339 nm in the presence of saccharopine and enzyme (14) .
Substrates and cofactors used in the saccharopine dehydrogenase assays were dissolved in 0.1 M potassium phosphate buffer (pH 6.8). Substrates and cofactors used in the saccharopine reductase assays were dissolved in 0.1 M glycine-NaOH buffer (pH 9.5).
A 2000 recording spectrophotometer (Gilford Instrument Laboratories, Inc., Oberlin, Ohio) with auxiliary offset control was used for spectrophotometric assays.
Protein concentrations, where indicated, were determined by the method of Waddell (25) . Metabolism of labeled lysine. Incubation of L-lysine-6-14C with NADH and a-KG in the presence of a yeast enzyme preparation produced labeled saccharopine. The identity of the saccharopine was confirmed by paper chromatography in five solvent systems against a saccharopine standard active in the saccharopine dehydrogenase and reductase assays.
RESULTS
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The lysine conversions to saccharopine in 2 hr achieved by enzyme preparations from three strains are compared in the three radiochromatogram scans represented in Fig. 2 which bore no suppressor failed to produce saccharopine in the labeled assay, whereas all lyi-i strains tested bearing either the SI or SI, suppressors exhibited reduced but significant saccharopine production. Enzyme preparations from lysineless mutants with lesions at other sites (1y2, lyg) behaved like wild type in the lysineto-saccharopine assay. Metabolism of labeled a-AAA. Incubation of DL-a-AAA-6-14C with an undialyzed wild-type yeast enzyme preparation yielded labeled saccharopine. The undialyzed system required ATP, but after dialysis reduced NADP Mg2+ and adenosine triphosphate were required.
There was no evidence in our wild-type labeled incubation mixtures for the production of any intermediates between a-AAA and saccharopine. Indirect evidence has previously been presented for an adenylated intermediate (19) mediates between a-AAA and saccharopine was, however, found in our studies by using enzyme preparations extracted from mutants blocked before saccharopine. The a-AAA conversion to saccharopine was compared in enzyme preparations from three strains. The first, a wild-type strain (F2), showed extensive conversion of a-AAA to saccharopine. Since we employed the DL-a-AAA as substrate and assuming that only the L-a-AAA is converted to saccharopine, the wild-type conversion in 4 hr appeared to be close to 100%. The second, an unsuppressed lyg-l mutant strain (X1012-lD),
showed no conversion of a-AAA to saccharopine, suggesting that the block in saccharopine reductase in this Iyg mutant strain is total. The solvent systems employed gave clear demonstration that no radioactive material resembling sackND LYSINE BIOSYNTHESIS 113 charopine is produced by this mutant strain. It was evident, however, that small amounts of radioactive material appeared at other sites on the chromatograms and as a shoulder on the a-AAA peak. The third strain, a supersuppressed lyg-l mutant (MO-73-18C), exhibited considerably reduced saccharopine production in 4 hr compared to wild type. These results were confirmed in four different solvent systems. The accumulation of labeled intermediates between a-AAA and saccharopine was most clearly demonstrated by using the unsuppressed lyWl mutant (blocked before saccharopine) when the incubation mixture was chromatographed in a n-butyl alcohol-acetic acid-water solvent system. Two new peaks were differentiated, neither of which was saccharopine. Comparison of the top and middle scans reveals the dependence of the dialyzed enzyme on NADPH for a reductive step in the metabolism of a-AAA. The middle scan reveals two new peaks positioned on either side of a-AAA in this solvent system. The large peak to the left of a-AAA has an RF value close to saccharopine in this solvent system. The fact that it is clearly not saccharopine is revealed in other solvent systems and by its reaction with p-dimethylaminobenzaldehyde demonstrated in the lowest scan. The reaction produced an orange adductwhich migrated at a new site on the chromatogram. These observations taken together with previous work (20, 21) suggest that the intermediate peak migrating to the left of a-AAA is the 6-semialdehyde of a-AAA or its cyclized form (51-piperidine-6-carboxylate). The smaller peak migrating to the right of a-AAA in this system has not yet been identified. These two new peaks were also observed, but to a lesser extent, in supersuppressed lyg-l incubations. It is clear that only in the reduction or complete absence of saccharopine reductase activity do the steady state concentrations of these intermediates increase to discernible levels. Table 4 compares the production of labeled saccharopine from a-AAA-6-'4C by supersuppressed and that by unsuppressed enzyme preparations. The top three strains (L Y, lY4, and lY-1_ SI) are wild type with respect to this portion of the pathway and, as expected, are able to and MO-73-18C) also demonstrated a low level of saccharopine production, indicating that the effect of SI was to relieve the lyg-l mutant lesion and allow synthesis of saccharopine reductase.
Comparison of the rates of saccharopine formation by wild type and supersuppressed enzyme incubations, sampled at 1, 2, and 4 hr, indicated that the supersuppressed enzyme preparation probably functioned at a rate less than 10% that of wild type. The finding that the unsuppressed IY2-1 strain tested was also unable to accumulate labeled saccharopine is in agreement with localization of the bY2 metabolic block immediately after a-AAA in lysine biosynthesis (13) and indicates that this block is probably total. The inability of supersuppressed IY2-1 to form any labeled product, however, is inconsistent with its ability to grow on NH4+ in the absence of lysine or a-AAA and suggested the possibility that the supersuppressed lY2-1 enzyme might be labile under the condition employed.
To test this possibility, a whole-cell incubation system was used to assay the amino acid pool for intermediates produced from labeled a-AAA by a supersuppressed Y2-1 strain.
A wild-type control strain (MO-59-1 3A) showed considerable labeled saccharopine and lysine production from a-AAA, whereas an unsuppressed mutant strain (MO-49-14D) gave no indication of any conversion of labeled a-AAA. Whole-cell incubations of a supersuppressed IY2-1 strain (BM-6-MO-49-14D) revealed a small amount of labeled saccharopine production, thus firmly establishing a consistent pattern regarding supersuppression of the Y2-1, lY9 1, and lyi-i mutant lesions.
Spectrophotometric assays for saccharopine dehydrogenase and saccharopine reductase. For kinetic studies, continuous optical assays are more convenient than discontinuous radioactive assays. To study the specific effect of a supersuppressor gene (SI) on saccharopine dehydrogenase and saccharopine reductase, spectrophotometric assays (14, 22) were utilized. Table  5 compares the specific activities of supersuppressed and wild-type saccharopine dehydrogenase. Depending on the mode of expression of the results, the supersuppressed activity was found to be between 6 and 10% of wild-type activity, confirming the preliminary estimate made with labeled lysine.
Since the reduced levels of enzyme activity in the supersuppressed mutant might have been due either to a reduced rate of synthesis of the wild-type enzyme or to an enzyme alteration, or both, a study was made of the Michaelis A similar study of the effect of SI on saccharopine reductase in a lyg-l SI strain produced the results indicated in Table 7 . Here again, the Km value for each substrate of supersuppressed saccharopine reductase was greater than the comparable value for the wild-type enzyme. A previous report of Km values for a more extensively purified saccharopine reductase preparation again compares favorably (14) .
The demonstration that SI alters both saccharopine reductase and saccharopine dehydrogenase in lY9-l SI and lyi-i SI strains, respectively, suggested a control experiment to check whether the saccharopine dehydrogenase in a strain bearing a supersuppressor-altered saccharopine reductase (Iy9-l SI) would be wild type or altered. Recent findings have demonstrated the similarity between the lysine biosynthetic route in yeast ( Fig. 1 ) and the major route of lysine degradation in humans. Higashino, Tsukada, and Lieberman (11) have demonstrated that rat liver will catalyze the conversion of lysine to saccharopine and suggested that this may be the initial step in the major lysine degradative pathway in mammals. Studies in humans have indicated the probable relationship between certain cases of elevated blood lysine level (hyperlysinemia) and an apparently heritable disease in humans (26). The demonstration of a metabolic block at an early step in lysine degradation (27) and the indication that saccharopine is a direct product of lysine conversion in humans (12) make the lyi-i yeast mutant an attractive experimental model for this human condition.
Accumulation of high levels of saccharopine in patients believed to carry another inborn error in lysine metabolism [saccharopinuria (4)], indicating an inability to degrade saccharopine suggests the lyg-i yeast mutant as a model for this human condition.
The possibilities of a general approach to the treatment of genetic disease by "euphenic" means (15) and of the medicogenetic application of gene products of specific suppressors (17) have been considered.
